Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
- 1 August 1996
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (9) , 1523-1529
- https://doi.org/10.1016/0959-8049(96)00132-3
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamideSupportive Care in Cancer, 1996
- Pharmacology of the human metabolites of dolasetron, an antiemetic 5‐HT3 receptor antagonistDrug Development Research, 1995
- OndansetronDrugs, 1993
- OndansetronEuropean Journal Of Cancer, 1993
- The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nursesEuropean Journal Of Cancer, 1992
- Human dolasetron pharmacokinetics: I. Disposition following single‐dose intravenous administration to normal male subjectsBiopharmaceutics & Drug Disposition, 1992
- 5-HT3 Receptor AntagonistsDrugs, 1991
- OndansetronDrugs, 1991
- On the receiving end—patient perception of the side-effects of cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1983
- Strategies for enhancing patient complianceJournal of Community Health, 1980